Spruce Biosciences Reports Positive Long-Term Clinical Data for TA-ERT in Sanfilippo Syndrome Type B, Paving Way for FDA Approval

summarizeSummary

Spruce Biosciences presented positive long-term clinical data for its TA-ERT in Sanfilippo Syndrome Type B, showing durable reduction of heparan sulfate and preserved cognitive and motor outcomes, positioning it as a potential first-in-class therapy.

check_boxKey Events

• Positive Long-Term Clinical Data

  Spruce Biosciences announced long-term data (up to six years) for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB), demonstrating rapid and durable reduction of heparan sulfate and preserved cognitive and non-cognitive outcomes.

• Stabilization of Cognitive and Motor Skills

  TA-ERT treatment stabilized cognitive function (Bayley-III Cognitive Raw Score), receptive and expressive communication, and fine and gross motor skills, contrasting with declines observed in untreated natural history patients.

• Potential First-in-Class Therapy

  The company highlights TA-ERT's potential as the first disease-modifying treatment option for MPS IIIB, a fatal condition with no currently approved therapies.

• Clear Regulatory Path

  The data strengthens confidence in advancing the program through a Biologics License Application (BLA) submission and potential U.S. FDA approval, with the possibility of accelerated approval.

auto_awesomeAnalysis

Spruce Biosciences announced highly significant long-term clinical data for its tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). The data, presented at a major symposium, demonstrates TA-ERT's potential as the first disease-modifying treatment for this fatal genetic disorder. The sustained normalization of key biomarkers and preservation of cognitive and motor skills over six years, coupled with a favorable safety profile, significantly de-risks the program and strengthens the path towards a Biologics License Application (BLA) submission and potential FDA approval. This positive development is a critical catalyst for the company, given the high unmet medical need and the transformative potential for patients.